Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Carcinoma, Non-Small-Cell Lung 13Multiple Myeloma 12Lymphoma, Large B-Cell, Diffuse 11Lymphoma 11Hodgkin Disease 11Lymphoma, Non-Hodgkin 10Lymphoma, Follicular 8Neoplasms 7Lymphoma, Mantle-Cell 7Leukemia, Lymphocytic, Chronic, B-Cell 7Burkitt Lymphoma 7Breast Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6Recurrence 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Neuroblastoma 6Blast Crisis 6Sezary Syndrome 5Prostatic Neoplasms 5Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Mycosis Fungoides 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Large-Cell, Anaplastic 5Lymphoma, Extranodal NK-T-Cell 5Lymphoma, B-Cell, Marginal Zone 5Brain Neoplasms 5

Interventions

spartalizumab 1Vorinostat 1Ranibizumab 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × von Hippel-Lindau Disease × Vorinostat × Clear all
NCT02108002 2018-09-14

Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
7 enrolled

von Hippel-Lindau Disease, Hemangioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡